Showing results (411-420 of 494) with videos related to
Sort By:
Pageof 50
Annals of Surgical Oncology|January 3, 2021
Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG)Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.Annals of Surgical Oncology|April 28, 2021
Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)Carolyn Nessim, Chandrajit P Raut, Dario Callegaro, et al.The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.Cancer|August 16, 2020
Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWGWinan J van Houdt, Marco Fiore, Francesco Barretta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteriaAugustinus P T van der Ploeg, Alexander C J van Akkooi, Piotr Rutkowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced MelanomaCaroline Robert, Georgina V Long, Benjamin Brady, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.Pageof 50